Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine

Abstract

Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine ABS TRACTObjective: The aims of present study were 1) to evaluate cardiac valve characteristics, 2) to determine the plasma concentrations of fibrinogen, high sensitivity C-reactive protein (hsCRP), adiponectin, and tumor necrosis factor-α (TNF-α) in the obese women before and after 19 months sibutramine treatment in the obese women. Methods: Sixty obese women were enrolled in this prospective, randomized study. Thirty women received 10 mg once daily dose of sibutramine for 19 months. The rest of the obese women received 15 mg once daily dose of sibutramine for 19 months. All patients were evaluated with echocardiography. Plasma levels of adiponectin and TNF-α were measured by enzyme-linked immunosorbent assay (ELISA) and hsCRP by immunoturbimetric assay. Student paired and unpaired t tests were used to compare the 10 mg or 15 mg dose sibutramine effects either in groups or between the groups. Results: There were no signs of significant regurgitation or thickening of the mitral and aortic valves on echocardiographic evaluation performed after 19 months of treatment. Parameters of systolic function after 10 or 15 mg treatment were not different from pretreatment characteristics. Minimal tricuspid regurgitation was found in one (1/27) patient treated with 10 mg sibutramine after 19 months. Among obese patients treated with 15 mg sibutramine one patient (1/28) had minimal mitral valve regurgitation and 2 patients (2/28) had minimal aortic insufficiency. Stage II diastolic dysfunction in the 15 obese treated with 15 mg regressed to stage I diastolic dysfunction (50%). Stage II diastolic dysfunction in the 10 obese treated with 10 mg regressed to stage I diastolic dysfunction (33.3%). Mean levels of TNF-α(p=0.04), fibrinogen (p=0.03) and hsCRP (p=0.04)i decreased and adiponectin (p=0.03) levels increased in the obese treated with 10 mg sibutramine. Likewise, in the patients treated with 15 mg sibutramine, mean levels of TNF-α(p=0.01), fibrinogen (p= 0.02), and hsCRP (p= 0.04) decreased and adiponectin (p= 0.02) levels increased. Conclusion: Nineteen months of sibutramine treatment does not affect heart valve and systolic functions, however, diastolic dysfunction severity reduced with sibutramine treatment. Also In addition, mean levels of adiponectin, TNF-α, fibrinogen and hs-CRP change with 19 months sibutramine treatment. (Anadolu Kardiyol Derg 2010; 10: 226-32)

Effects of Pterygium Surgery on Holladay Eqiuvalent Keratometry Readings

“…65% of the mean of the keratometry values in each examined zone is calculated. For irregular corneas such as postrefactive, postkeratoplasty, and scarred corneas, this report makes it possible to obtain a mean K value from a larger surface 6,11 . In addition, another advantage of EKR65 data is that it can be used directly in biometric measurements 4 .…”

5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators

“…In some other clinical studies, sibutramine did not increase blood pressure in obese patients [ 103 , 104 ]. Besides, patients taking sibutramine experienced a significant increase in heart rate [ 83 , 105 , 106 , 107 , 108 , 109 ], but without difference in the overall status of the cardiac valves compared to placebo subjects [ 105 , 110 , 111 , 112 ]. Otherwise, sibutramine’s most frequently encountered adverse effects were constipation, dry mouth, headache, insomnia, and nausea.…”

An Exploratory Critical Review on TNF-α as a Potential Inflammatory Biomarker Responsive to Dietary Intervention with Bioactive Foods and Derived Products

“…Only a limited number of drugs (e.g., orlistat, naltrexone-bupropion, liraglutide, phentermine-topiramate, semaglutide) are currently approved by the Food and Drug Administration as an alternative therapy to promote weight loss in human adults [ 162 ]. We collected and analysed several human studies where the participants were treated with some of these anti-obesity drugs, and changes in body weight and in the levels of TNF-α were reported [ 29 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 ] ( Table S9 ). Our main aim was to evaluate the relevance and significance of these changes and whether there was a clear association between body weight and TNF-α in response to drug treatment.…”

“…The studies were primarily conducted in obese/overweight adults of both sexes (mixed) which, in some cases, were also reported to be associated with other disorders such as T2D, hypertension, dyslipidaemia, etc. Some of the investigated trials were carried out using different chemical drugs (orlistat, L-carnitine, sibutramine, diacerein, hydroxychloroquine (HCQ), troglitazone, rosiglitazone, rimonabant, lacidipine, candesartan, metformin (MET) [ 29 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 ], and various other studies tested the effects of the protein/peptide-like molecules etanercept, exenatide, and liraglutide [ 176 , 177 , 178 , 179 ]. The drug intervention period varied from ≈60 d up to more than a year, and the comparison was generally done against lifestyle modifications (i.e., LCD) and/or against a widely used reference drug (i.e., MET).…”

“…In this study, the highest dose promoted a slightly higher reduction in TNF-α levels than the lower dose (−0.5 pg/mL). Nevertheless, no information on the significance of the differences between the two groups was reported, and it was not addressed whether the reduction in TNF-α was associated with body weight reduction [ 168 ]. We found one additional study that reported a significantly better reduction in body weight with sibutramine + LCD.…”